Financial Health Assessment: Cerastes Ltd

1. Financial Health Score: B

Explanation: Cerastes Ltd exhibits the financial equivalent of a robust immune system but is currently fighting off an acute infection. The company possesses a exceptionally strong liquidity position with no long-term debt, acting as a formidable shield against immediate financial distress. However, the latest financial year (2026) reveals symptoms of a significant profitability issue—a notable loss that has depleted retained earnings. The overall grade is a 'B' because while the patient is in no immediate danger of collapse, the sudden decline in financial health requires prompt diagnostic attention to prevent a chronic condition.

2. Key Vital Signs

• Liquidity (Blood Pressure): 3.03:1 Current Ratio Calculated as Current Assets (£245,544) divided by Current Liabilities (£80,901). This is a very healthy reading. The company has more than enough liquid assets to cover its short-term obligations, indicating no risk of a financial heart attack (insolvency) in the near term.
• Cash Reserves (Hydration Levels): £227,491 Cash levels have remained remarkably stable between 2025 (£229,049) and 2026 (£227,491). Despite a significant loss, the company did not dry up its cash reserves, suggesting the loss may have been a non-cash write-down or that cash was preserved through other means.
• Profitability (Weight/Mass): Loss of £54,594 This is the most concerning vital sign. Retained profits dropped from £227,450 in 2025 to £172,856 in 2026. Because no dividends were declared, this £54,594 decrease represents a direct loss for the year. The patient has experienced sudden, unintended weight loss.
• Leverage (Cholesterol): Nil Long-Term Debt The balance sheet shows zero long-term liabilities. The company is not burdened by high interest payments, meaning its financial arteries are clear.
• Debtors (Digestion): £18,053 Debtors dropped drastically from £104,554 to £18,053. This suggests the company successfully collected outstanding fees from the previous year, which explains how cash remained stable despite making a loss.

3. Diagnosis

Diagnosis: Acute Profitability Shock with Strong Constitutional Resilience

The financial data reveals a business that has suffered a sudden reversal in profitability after several years of healthy growth. Between 2021 and 2025, the company steadily grew its net assets from £73,893 to £238,616—a strong track record of financial health. However, the year ending March 2026 shows a significant hemorrhage in the Profit & Loss reserve.

The underlying business health remains structurally sound. The "skeleton" of the company is strong: cash reserves are high, debt is minimal, and creditors have been reduced. The fact that cash levels did not drop despite a £54k loss suggests this loss may include significant non-cash items (such as impairment or write-offs) or that the company burned through cash from operations but offset it by collecting the large debtor book from 2025.

The presence of a provision for liabilities (£6,287) and the addition of £12,474 in new plant/machinery assets suggest the company is still investing and preparing for future obligations, rather than winding down.

4. Recommendations

1. Identify the Source of the Bleeding: Conduct an immediate review of the 2026 Profit & Loss account to determine the exact nature of the £54,594 loss. Was it a drop in revenue (loss of clients), an increase in operational costs, or a one-off write-off? You cannot cure what you cannot diagnose.
2. Monitor Cash Flow Vitals Closely: While current cash levels are healthy, a prolonged period of losses will eventually drain these reserves. Implement a 13-week rolling cash flow forecast to ensure the "hydration levels" remain stable.
3. Review Tax Liabilities: The "Other taxation and social security" liability stands at £57,887. Given the loss in 2026, ensure that Corporation Tax payments on previous profits are managed efficiently and that the company is not building up liabilities it cannot service if losses persist.
4. Protect the Cash Cushion: Until profitability is restored, defer any non-essential capital expenditure. While the recent investment in plant and machinery (£12,474) may be necessary, major new investments should be put on hold until the patient is out of the woods.